Plumeria obtuse L. (Apocynaceae) is an ornate outdoor plant. The plant was traditionally used during accidentalinjuries. However, the pharmacognosy of this plant is very poorly explored. Therefore, we have conducted this study to assess the distinctive qualities of the P. obtusa. To investigate P. obtusa seed pods’ preliminary pharmacognostic, physical-chemical, phytochemical, microscopic, and phytoconstituent potential. Initially, the shape and microscopic characteristics of plant seed pods were assessed. Physicochemical analysis was used for the standardization. Utilizing several chemical techniques, phytoconstituents were evaluated qualitatively. This was followed by quantitative estimation and analytical profiling of various phytoconstituents. The basic characteristics of the seed pod have been documented by macroscopy to be its brown color, sweet aroma, bitter flavor, coarse texture, and rough fracture. Microscopy showed the existence of vascular bundles, lignified fibers, calcium oxalate crystals and arteries. The results of the physicochemical analysis revealed no foreign organic matter, 2.8 % weight-average moisture content and a high total ash value of 14.80 compared to an acid insoluble ash value of 0.70, which indicated that there was less inorganic matter in the plant. The extractive values were 3.93, 6.03 and 10.16 % w/w for water soluble, alcohol soluble and hydro-alcoholic soluble extracts respectively. Flavonoids, glycosides, saponins, phenolic constituents, tannins and carbohydrates were found during early phytochemical analysis. Instrumental analysis has given an idea about functional groups present whereas GCMS technique helped in identification of phytoconstituents. The results of this study can be significantly used as a reference support for quality control and standardization of P. obtusa and preparation of a monograph of plant.

<em>Sansevieria cylindrica</em> (SC) Bojer ex Hook. (Asparagaceae) and <em>Plumeria obtusa</em> (PO) L. (Apocynaceae) are indoor and outdoor ornamental plants respectively. These plants are traditionally used by the local healers during accidental injuries. However, their toxicological properties are very poorly explored over folkloric usage. Therefore, the present study evaluated the toxic potencies of SC leaves and PO seed Hydro-Alcoholic Extract (SCPOHAE) through acute oral dose (14-days) administration in female Wistar rats. Safety of the SCPOHAE was evaluated as per Organization for Economic Co-operation and Development (OECD) Acute Oral Toxicity study guidelines 423. The female Wistar rats were divided into three groups (n=3). A single oral dose of 2000 mg/kg of body weight of individual extract and 1:1 blend was administered to each animal. The animals were closely observed for clinical signs, neurobehavioral changes, morbidity, and mortality if any for the first half an hour and then every hour for the first four hours followed by observation every 24–hours for 14 days. Changes in food and water consumption, body weight were monitored daily during the study. On day 1 and day 15 blood samples were collected to evaluate changes in the hematology and biochemistry parameters. The urine samples were also collected for urine analysis parameters. Animals were sacrificed on day 15 and organ samples of liver and kidney were collected for histopathological findings. The SCPOHAE individually and also as 1:1 blend at the limit dose (2000 mg/kg, body weight) did not cause death and did not induce any remarkable and abnormal clinical signs, indicative of systemic toxicity, in rats during the treatment period of 14–days. The statistically non-significant small differences in the body weight were observed. <strong>Conclusion:</strong> The oral administration of SCPOHAE did not cause any systemic toxic effects. In conclusion, the No-observed-Adverse-Effect Level (NOAEL) of these extracts in rats was found to be greater than 2000 mg/kg.

The research on drug development life cycle and bringing sole new drug to the market is a million dollar question for pharmaceutical organization. Any clinical trial consumes average of 10 to 15 years and USD 1.5-2.0 billion with uncertainty of medications for its effectiveness for human use. Hardly, one out of 10 compounds entering into the clinical trial that reaches to the market rendering a major loss to pharmaceutical or biotech company in case of trial failure. Conversely, with changing time and an increase in the number of medicines approved by regulatory authorities, the regulatory teams are increasing networks for monitoring and assembling adverse event reports from varied sources. This in turn, has increases annual exponential rise in data volumes and the companies are facing a huge challenge in processing it. To meet such challenges, organizations must sharpen their ability to introduce new wearables for clinical trials and provide advanced cognitive solution to handle large and complex datasets. This has summoned concepts like Artificial Intelligence to expedite medical science and clinical trial and pharmacovigilance attain success.